Page last updated: 2024-12-08

aminopyridazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aminopyridazine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID230373
CHEMBL ID5170155
MeSH IDM0501924

Synonyms (44)

Synonym
aminopyridazine
nsc-25228
5469-70-5
nsc25228
3-aminopyridazine
AKOS000303286
pyridazin-3-amine
letvjwllimjade-uhfffaoysa-
inchi=1/c4h5n3/c5-4-2-1-3-6-7-4/h1-3h,(h2,5,7)
EN300-80851
A7941
pyridazin-3-ylamine
FT-0600204
AM20100349
PB17217
BP-21190
SY017896
mfcd01529869
LETVJWLLIMJADE-UHFFFAOYSA-N
3-pyridazinamine
pyridazine-3-amine
pyridazyl amine
3-amino-pyridazine
pyridazineamine
PS-9352
3-pyridazinamin
AC-23159
J-511727
3-aminopyridazine, 97%
DTXSID30282256
CS-D1151
CHEMBL5170155 ,
imino-pyridazine
BCP22422
tert-butyl?1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate
SB10179
bdbm50589297
XGV ,
nsc 25228
Z991531024
YQP8QA3E57
2,3-dihydro-3-iminopyridazine
(pyridazin-3-yl)amine
pyridazine, 3-amino-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The developed method was successfully applied to the pharmacokinetic study of ZW14 in beagle dogs after oral and intravenous administration of 2 mg/kg."( A rapid and sensitive HPLC-MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study.
Deng, J; Guo, J; Liang, F; Liu, P; Lv, B; Tang, J; Xie, H, 2015
)
0.66

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of ZW14 was 26."( A rapid and sensitive HPLC-MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study.
Deng, J; Guo, J; Liang, F; Liu, P; Lv, B; Tang, J; Xie, H, 2015
)
0.66

Dosage Studied

ExcerptRelevanceReference
" Oral dosing of these compounds in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycaemic control."( Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
Bursalaya, B; Deaton, L; DiDonato, M; Filippi, CM; Glynne, R; Hao, X; Harb, G; Hering, BJ; Herman, AE; Jin, Q; Kamireddy, A; Laffitte, B; Lamb, J; Li, J; Liu, Y; Martin Seidel, H; McNamara, P; Meeusen, S; Mo, T; Nguyen-Tran, V; Powers, AF; Qiu, M; Shen, W; Suarez-Pinzon, WL; Swafford, A; Taylor, B; Turk, CN; Walker, J; Wu, T; Yan, S; Zhang, YQ, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aspartate aminotransferase, cytoplasmicHomo sapiens (human)IC50 (µMol)100.00005.39005.39005.3900AID1850919
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
gluconeogenesisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glycerol biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate catabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate metabolic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
Notch signaling pathwayAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to aspartateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
glutamate catabolic process to 2-oxoglutarateAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cellular response to insulin stimulusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
response to glucocorticoidAspartate aminotransferase, cytoplasmicHomo sapiens (human)
fatty acid homeostasisAspartate aminotransferase, cytoplasmicHomo sapiens (human)
aspartate biosynthetic processAspartate aminotransferase, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
L-aspartate:2-oxoglutarate aminotransferase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
phosphatidylserine decarboxylase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
pyridoxal phosphate bindingAspartate aminotransferase, cytoplasmicHomo sapiens (human)
L-cysteine transaminase activityAspartate aminotransferase, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytoplasmAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
extracellular exosomeAspartate aminotransferase, cytoplasmicHomo sapiens (human)
cytosolAspartate aminotransferase, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1850919Inhibition of GOT1 (unknown origin) using aspartic acid and alpha-ketoglutaric acid as substrates assessed as reduction in absorbance of NADH incubated for 20 mins in presence of MDH1 and NADH by HTS assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (31.58)18.7374
1990's0 (0.00)18.2507
2000's4 (21.05)29.6817
2010's7 (36.84)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.62 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (15.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (84.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]